Jean A Boutin

List of Publications by Citations

258 papers	8,494 citations	47 h-index	79 g-index
268 ext. papers	9,239 ext. citations	5.3 avg, IF	5.82 L-index

#	Paper	IF	Citations
258	Identification of the melatonin-binding site MT3 as the quinone reductase 2. *Journal of Biological Chemistry*, **2000**, 275, 31311-7	5.4	397
257	Myristoylation. *Cellular Signalling*, **1997**, 9, 15-35	4.9	330
256	Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. *Journal of Biological Chemistry*, **2003**, 278, 962-7	5.4	248
255	Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?. *British Journal of Pharmacology*, **2008**, 154, 1182-95	8.6	202
254	New selective ligands of human cloned melatonin MT1 and MT2 receptors. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2003**, 367, 553-61	3.4	198
253	Molecular tools to study melatonin pathways and actions. *Trends in Pharmacological Sciences*, **2005**, 26, 412-9	13.2	177
252	Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. *Journal of Biological Chemistry*, **2003**, 278, 18162-9	5.4	175
251	Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. *Biochemical Pharmacology*, **2001**, 61, 1369-79	6	155
250	Comment on "Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake". *Science*, **2007**, 315, 766; author reply 766	33.3	151
249	Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-3-3-binding switch in melatonin synthesis. *Proceedings of the National Academy of Sciences of the United States of America* , **2001**, 98, 8083-8	11.5	150
248	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. *Synapse*, **2000**, 35, 79-95	2.4	141
247	Structure and expression of the human histamine H4-receptor gene. *Biochemical and Biophysical Research Communications*, **2001**, 284, 301-9	3.4	120
246	NRH:quinone reductase 2: an enzyme of surprises and mysteries. *Biochemical Pharmacology*, **2005**, 71, 1-12	6	119
245	Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part?. *Cellular Signalling*, **2002**, 14, 573-83	4.9	117
244	New alpha-amino phosphonic acid derivatives of vinblastine: chemistry and antitumor activity. *Journal of Medicinal Chemistry*, **1991**, 34, 1998-2003	8.3	103
243	Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. *Biochemical Pharmacology*, **2005**, 71, 74-88	6	98
242	Cloning and characterization of the 5' flanking region of the human uncoupling protein 3 (UCP3) gene. *Biochemical and Biophysical Research Communications*, **1999**, 258, 278-83	3.4	95

241	Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization. *Journal of Biological Chemistry*, **2008**, 283, 7776-89	5.4	91
240	Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. *Diabetologia*, **2005**, 48, 569-77	10.3	87
239	S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 327, 809-19	4.7	82
238	Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands. *Journal of Medicinal Chemistry*, **2002**, 45, 2788-800	8.3	79
237	Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. *British Journal of Pharmacology*, **2007**, 150, 37-46	8.6	78
236	Cloning and molecular characterization of the novel human melanin-concentrating hormone receptor MCH2. *Molecular Pharmacology*, **2001**, 60, 632-9	4.3	78
235	Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. *Biochemical Journal*, **2008**, 413, 81-91	3.8	74
234	Detergent-free Isolation of Functional G Protein-Coupled Receptors into Nanometric Lipid Particles. *Biochemistry*, **2016**, 55, 38-48	3.2	73
233	New ligands at the melatonin binding site MT(3). *European Journal of Medicinal Chemistry*, **2006**, 41, 306-18	4.8	73
232	S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. *Molecular Cancer Therapeutics*, **2013**, 12, 1749-62	6.1	69
231	Genomic organization and characterization of splice variants of the human histamine H3 receptor. *Biochemical Journal*, **2001**, 355, 279-88	3.8	67
230	Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). *Journal of Neuroscience*, **2011**, 31, 16928-40	6.6	66
229	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase activities. Conjugations of phenolic and monoterpenoid aglycones in control and induced rats and guinea pigs. *Biochemical Pharmacology*, **1985**, 34, 2235-49	6	66
228	Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. *FEBS Letters*, **2004**, 578, 116-20	3.8	62
227	Unraveling Plant Natural Chemical Diversity for Drug Discovery Purposes. *Frontiers in Pharmacology* , **2020**, 11, 397	5.6	61
226	Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times. *Journal of Medicinal Chemistry*, **2016**, 59, 7167-76	8.3	61
225	Post-translational modification of Bid has differential effects on its susceptibility to cleavage by caspase 8 or caspase 3. *Journal of Biological Chemistry*, **2003**, 278, 15749-57	5.4	60
224	Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase. *Biochemical Journal*, **2005**, 388, 205-15	3.8	60

223	Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. *Journal of Medicinal Chemistry*, **2003**, 46, 1127-9	8.3	59
222	Combinatorial peptide libraries: robotic synthesis and analysis by nuclear magnetic resonance, mass spectrometry, tandem mass spectrometry, and high-performance capillary electrophoresis techniques. *Analytical Biochemistry*, **1996**, 234, 126-41	3.1	57
221	Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 2517-28	3.4	55
220	Structure-activity relationship studies of melanin-concentrating hormone (MCH)-related peptide ligands at SLC-1, the human MCH receptor. *Journal of Biological Chemistry*, **2001**, 276, 13554-62	5.4	55
219	High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2016**, 311, H44-53	5.2	54
218	Therapeutic perspectives for melatonin agonists and antagonists. *Journal of Neuroendocrinology*, **2003**, 15, 442-8	3.8	52
217	Food intake regulation in rodents: Y5 or Y1 NPY receptors or both?. *Canadian Journal of Physiology and Pharmacology*, **2000**, 78, 173-185	2.4	52
216	Functional invalidation of the autotaxin gene by a single amino acid mutation in mouse is lethal. *FEBS Letters*, **2007**, 581, 3572-8	3.8	51
215	Tyrosine protein kinase inhibition and cancer. *International Journal of Biochemistry & Cell Biology*, **1994**, 26, 1203-26		51
214	The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor. *British Journal of Pharmacology*, **2009**, 158, 1248-62	8.6	50
213	Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. *Journal of Pharmacology and Experimental Therapeutics*, **1999**, 290, 334-40	4.7	50
212	Quinone reductase 2 as a promising target of melatonin therapeutic actions. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 303-17	6.4	48
211	Melatonin from cerebrospinal fluid but not from blood reaches sheep cerebral tissues under physiological conditions. *Journal of Neuroendocrinology*, **2014**, 26, 151-63	3.8	47
210	Expression of the orphan GPR50 protein in rodent and human dorsomedial hypothalamus, tanycytes and median eminence. *Journal of Pineal Research*, **2010**, 48, 263-269	10.4	47
209	Substrate specificity and inhibition studies of human serotonin N-acetyltransferase. *Journal of Biological Chemistry*, **2000**, 275, 8794-805	5.4	46
208	GHSR-D2R heteromerization modulates dopamine signaling through an effect on G protein conformation. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 4501-4506	11.5	45
207	The active conformation of human glucokinase is not altered by allosteric activators. *Acta Crystallographica Section D: Biological Crystallography*, **2011**, 67, 929-35		45
206	Binding kinetics of glucose and allosteric activators to human glucokinase reveal multiple conformational states. *Biochemistry*, **2009**, 48, 5466-82	3.2	44

205	Quinone reductase 2 substrate specificity and inhibition pharmacology. *Chemico-Biological Interactions*, **2005**, 151, 213-28	5	44
204	Binding of prostaglandins to human PPARgamma: tool assessment and new natural ligands. *European Journal of Pharmacology*, **2001**, 417, 77-89	5.3	44
203	Melanin-concentrating hormone and its receptors: state of the art. *Canadian Journal of Physiology and Pharmacology*, **2002**, 80, 388-95	2.4	44
202	Myristoyl-CoA:protein N-myristoyltransferase activity in cancer cells. Purification and characterization of a cytosolic isoform from the murine leukemia cell line L1210. *FEBS Journal*, **1993**, 214, 853-67		44
201	The RFamide neuropeptide 26RFa and its role in the control of neuroendocrine functions. *Frontiers in Neuroendocrinology*, **2011**, 32, 387-97	8.9	43
200	Resistance to high-fat-diet-induced obesity and sexual dimorphism in the metabolic responses of transgenic mice with moderate uncoupling protein 3 overexpression in glycolytic skeletal muscles. *Diabetologia*, **2007**, 50, 2190-9	10.3	43
199	Expression of UCP3 in CHO cells does not cause uncoupling, but controls mitochondrial activity in the presence of glucose. *Biochemical Journal*, **2006**, 393, 431-9	3.8	42
198	Expression and regulation of the nuclear receptor RORalpha in human vascular cells. *FEBS Letters*, **2002**, 511, 36-40	3.8	42
197	Melatonin MT$_1$ and MT$_2$ receptors display different molecular pharmacologies only in the G-protein coupled state. *British Journal of Pharmacology*, **2014**, 171, 186-201	8.6	41
196	Insights into the redox cycle of human quinone reductase 2. *Free Radical Research*, **2011**, 45, 1184-95	4	41
195	Therapeutic potential of melatonin ligands. *Chronobiology International*, **2006**, 23, 413-8	3.6	40
194	Assessment of the Mulder and Van Doorn kinetic procedure and rapid centrifugal analysis of UDP-glucuronosyltransferase activities. *Journal of Proteomics*, **1984**, 9, 69-79		40
193	Old and new inhibitors of quinone reductase 2. *Chemico-Biological Interactions*, **2010**, 186, 103-9	5	39
192	Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. *Biochemical Pharmacology*, **2008**, 75, 2007-19	6	39
191	Is There Sufficient Evidence that the Melatonin Binding Site Is Quinone Reductase 2?. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 368, 59-65	4.7	39
190	Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery. *Acta Crystallographica Section F, Structural Biology Communications*, **2017**, 73, 174-183	1.1	37
189	Autotaxin. *Cellular and Molecular Life Sciences*, **2009**, 66, 3009-21	10.3	37
188	[125I]-S36057: a new and highly potent radioligand for the melanin-concentrating hormone receptor. *British Journal of Pharmacology*, **2001**, 133, 371-8	8.6	37

187	X-ray structural studies of quinone reductase 2 nanomolar range inhibitors. *Protein Science*, **2011**, 20, 1182-95	6.3	36
186	A Dimeric sesquiterpenoid from a Malaysian Meiogyne as a new inhibitor of Bcl-xL/BakBH3 domain peptide interaction. *Journal of Natural Products*, **2009**, 72, 480-3	4.9	36
185	Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPARgamma. *Biochemical and Biophysical Research Communications*, **2005**, 337, 521-5	3.4	36
184	Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 753-9	3.4	36
183	Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3). *Journal of Medicinal Chemistry*, **2002**, 45, 1853-9	8.3	35
182	Use of hydrophilic interaction chromatography for the study of tyrosine protein kinase specificity. *Biomedical Applications*, **1992**, 583, 137-43		35
181	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase(s) activities: comparison between human and mammalian species activities. *Chemico-Biological Interactions*, **1984**, 52, 173-84	5	35
180	Loss of quinone reductase 2 function selectively facilitates learning behaviors. *Journal of Neuroscience*, **2010**, 30, 12690-700	6.6	34
179	4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1617-22	2.9	34
178	Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. *Biochemical Pharmacology*, **2004**, 67, 667-77	6	34
177	Molecular and cellular pharmacological properties of 5-methoxycarbonylamino-N-acetyltryptamine (MCA-NAT): a nonspecific MT3 ligand. *Journal of Pineal Research*, **2010**, 48, 222-229	10.4	32
176	MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate. *Journal of Pineal Research*, **2008**, 45, 524-31	10.4	32
175	Synthesis of phenalene and acenaphthene derivatives as new conformationally restricted ligands for melatonin receptors. *Journal of Medicinal Chemistry*, **2000**, 43, 4051-62	8.3	32
174	Specific oncogenic activity of the Src-family tyrosine kinase c-Yes in colon carcinoma cells. *PLoS ONE* , **2011**, 6, e17237	3.7	32
173	Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines. *Journal of Medicinal Chemistry*, **2015**, 58, 7512-25	8.3	31
172	Regulation of murine airway responsiveness by endothelial nitric oxide synthase. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 281, L258-67	5.8	31
171	NPY receptor subtypes involved in the contraction of the proximal colon of the rat. *Regulatory Peptides*, **1998**, 75-76, 221-9		30
170	A generic approach for the purification of signaling complexes that specifically interact with the carboxyl-terminal domain of G protein-coupled receptors. *Molecular and Cellular Proteomics*, **2008**, 7, 1556-69	7.6	30

169	NPY receptor subtype in the rabbit isolated ileum. *British Journal of Pharmacology*, **1999**, 127, 795-801	8.6	30
168	Food intake regulation in rodents: Y5 or Y1 NPY receptors or both?. *Canadian Journal of Physiology and Pharmacology*, **2000**, 78, 173-185	2.4	30
167	SLC-1 receptor mediates effect of melanin-concentrating hormone on feeding behavior in rat: a structure-activity study. *Journal of Pharmacology and Experimental Therapeutics*, **2001**, 299, 137-46	4.7	30
166	In cellulo monitoring of quinone reductase activity and reactive oxygen species production during the redox cycling of 1,2 and 1,4 quinones. *Free Radical Biology and Medicine*, **2015**, 89, 126-34	7.8	29
165	The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells. *Scientific Reports*, **2019**, 9, 11829	4.9	29
164	Structure-activity relationships of a series of analogues of the RFamide-related peptide 26RFa. *Journal of Medicinal Chemistry*, **2011**, 54, 4806-14	8.3	28
163	Cytotoxic pentacyclic triterpenoids from Combretum sundaicum and Lantana camara as inhibitors of Bcl-xL/BakBH3 domain peptide interaction. *Journal of Natural Products*, **2009**, 72, 1314-20	4.9	28
162	Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries. *Molecular Diversity*, **1997**, 2, 135-46	3.1	28
161	Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors. *European Journal of Medicinal Chemistry*, **2004**, 39, 515-26	6.8	27
160	Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties. *Chemico-Biological Interactions*, **2016**, 258, 115-25	5	27
159	New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. *International Journal of Molecular Sciences*, **2013**, 14, 8948-62	6.3	26
158	Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). *European Journal of Medicinal Chemistry*, **2012**, 49, 310-23	6.8	25
157	Meganuclease-driven targeted integration in CHO-K1 cells for the fast generation of HTS-compatible cell-based assays. *Journal of Biomolecular Screening*, **2010**, 15, 956-67		25
156	Combinatorial chemistry for the generation of molecular diversity and the discovery of bioactive leads. *Chemometrics and Intelligent Laboratory Systems*, **1998**, 43, 43-68	3.8	25
155	The emergence of selective 5-HT 2B antagonists structures, activities and potential therapeutic applications. *Mini-Reviews in Medicinal Chemistry*, **2004**, 4, 325-30	3.2	25
154	Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human 1A-adrenoceptors. *Biochemical Journal*, **1999**, 343, 231	3.8	25
153	Ligand modulation of [35S]GTPgammaS binding at human alpha(2A), alpha(2B) and alpha(2C) adrenoceptors. *Cellular Signalling*, **2002**, 14, 829-37	4.9	24
152	Molecular pharmacology of the mouse melatonin receptors MT and MT *European Journal of Pharmacology*, **2012**, 677, 15-21	5.3	23

151	Microfluidic platform for optimization of crystallization conditions. *Journal of Crystal Growth*, **2017**, 472, 18-28	1.6	22
150	Rational design of a low molecular weight, stable, potent, and long-lasting GPR103 aza-β-pseudopeptide agonist. *Journal of Medicinal Chemistry*, **2012**, 55, 7516-24	8.3	22
149	Appetite-boosting property of pro-melanin-concentrating hormone(131-165) (neuropeptide-glutamic acid-isoleucine) is associated with proteolytic resistance. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 302, 766-73	4.7	22
148	Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 356, 681-92	4.7	21
147	Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 3426-36	3.4	21
146	Integrated system for the screening of the specificity of protein kinase inhibitors. *Biochemical Pharmacology*, **1993**, 46, 439-48	6	21
145	Oxidative stress and neurodegeneration: The possible contribution of quinone reductase 2. *Free Radical Biology and Medicine*, **2018**, 120, 56-61	7.8	20
144	Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands. *European Journal of Medicinal Chemistry*, **2011**, 46, 1835-40	6.8	20
143	Characterization of the Mel1c melatoninergic receptor in platypus (Ornithorhynchus anatinus). *PLoS ONE*, **2018**, 13, e0191904	3.7	19
142	Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 8339-48	3.4	19
141	A simple theoretical model for fluorescence polarization binding assay development. *Journal of Biomolecular Screening*, **2006**, 11, 949-58		19
140	Investigation of S-farnesyl transferase substrate specificity with combinatorial tetrapeptide libraries. *Cellular Signalling*, **1999**, 11, 59-69	4.9	19
139	Melatonin receptor ligands: A pharmaco-chemical perspective. *Journal of Pineal Research*, **2020**, 69, e12672	10.4	18
138	Binding mode prediction and MD/MMPBSA-based free energy ranking for agonists of REV-ERBβ/NCoR. *Journal of Computer-Aided Molecular Design*, **2017**, 31, 755-775	4.2	18
137	Recombinant human melatonin receptor MT1 isolated in mixed detergents shows pharmacology similar to that in mammalian cell membranes. *PLoS ONE*, **2014**, 9, e100616	3.7	18
136	Evaluation of high performance liquid chromatography/electrospray mass spectrometry with selected ion monitoring for the analysis of large synthetic combinatorial peptide libraries. *Rapid Communications in Mass Spectrometry*, **1997**, 11, 1971-1976	2.2	18
135	Detection of the human GPR50 orphan seven transmembrane protein by polyclonal antibodies mapping different epitopes. *Journal of Pineal Research*, **2007**, 43, 10-5	10.4	18
134	Comparative analysis of melanin-concentrating hormone structure and activity in fishes and mammals. *Peptides*, **2004**, 25, 1623-32	3.8	18

133	Description of the constitutive activity of cloned human melatonin receptors hMT(1) and hMT(2) and discovery of inverse agonists. *Journal of Pineal Research*, **2012**, 53, 29-37	10.4	17
132	Limitations of the coupling of amino acid mixtures for the preparation of equimolar peptide libraries. *Molecular Diversity*, **1997**, 3, 43-60	3.1	17
131	S18986: a positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF mRNA and protein expression in rat primary cortical neuronal cultures. *European Journal of Pharmacology*, **2007**, 561, 23-31	5.3	17
130	Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform. *Biochemical Journal*, **2003**, 369, 667-73	3.8	17
129	A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor. *International Journal of Obesity*, **2004**, 28, 628-39	5.5	17
128	Combinatorial peptide synthesis: statistical evaluation of peptide distribution. *Trends in Pharmacological Sciences*, **1996**, 17, 8-12	13.2	17
127	Camphoroquinone reduction: another reaction catalyzed by rat liver cytosol 3 alpha-hydroxysteroid dehydrogenase. *BBA - Proteins and Proteomics*, **1986**, 870, 463-72		17
126	Indirect evidences of UDP-glucuronosyltransferase heterogeneity: how can it help purification?. *Drug Metabolism Reviews*, **1987**, 18, 517-51	7	17
125	Studies of UDP-glucuronosyltransferase activity toward eugenol, using a gas chromatographic method of measurement. *Analytical Biochemistry*, **1983**, 135, 201-7	3.1	17
124	A Chemical Library to Screen Protein and Protein□ligand Crystallization Using a Versatile Microfluidic Platform. *Crystal Growth and Design*, **2018**, 18, 5130-5137	3.5	16
123	New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 986-96	3.4	16
122	Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes. *European Journal of Cancer & Clinical Oncology*, **1989**, 25, 1311-6		16
121	Assay of tyrosine protein kinase activity from HL-60 by high-performance liquid chromatography for specificity studies. *Analytical Biochemistry*, **1990**, 190, 32-8	3.1	16
120	Inhibition studies of microsomal UDP-glucuronosyltransferase activities by furosemide and salicylamide. *Pharmacological Research Communications*, **1984**, 16, 227-41		16
119	Characterization of the various functional pathways elicited by synthetic agonists or antagonists at the melatonin MT and MT receptors. *Pharmacology Research and Perspectives*, **2020**, 8, e00539	3.1	16
118	Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist. *ChemMedChem*, **2013**, 8, 1830-45	3.7	15
117	Molecular pharmacology of adipocyte-secreted autotaxin. *Chemico-Biological Interactions*, **2008**, 172, 115-24	5	15
116	Cellular knock-down of quinone reductase 2: a laborious road to successful inhibition by RNA interference. *Biochimie*, **2007**, 89, 1264-75	4.6	15

115	Characterization and regulation of a CHO cell line stably expressing human serotonin N-acetyltransferase (EC 2.3.1.87). *Cellular and Molecular Life Sciences*, **2002**, 59, 1395-405	10.3	15
114	Assessments of cellular melatonin receptor signaling pathways: β-arrestin recruitment, receptor internalization, and impedance variations. *European Journal of Pharmacology*, **2018**, 818, 534-544	5.3	15
113	4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 2683-7	2.9	14
112	Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 2963-74	3.4	14
111	Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2316-9	2.9	14
110	High-throughput screening of novel antagonists on melanin-concentrating hormone receptor-1. *Acta Pharmacologica Sinica*, **2008**, 29, 752-8	8	14
109	New substrate analogues of human serotonin N-acetyltransferase produce in situ specific and potent inhibitors. *FEBS Journal*, **2004**, 271, 418-28		14
108	Purification of the recombinant human serotonin N-acetyltransferase (EC 2.3.1.87): further characterization of and comparison with AANAT from other species. *Protein Expression and Purification*, **2004**, 38, 84-98	2	14
107	Uncoupling protein-3 (UCP3) mRNA expression in reconstituted human muscle after myoblast transplantation in RAG2-/-/gamma c/C5(-) immunodeficient mice. *Journal of Biological Chemistry*, **2002**, 277, 47407-11	5.4	14
106	Studies of the potency of protein kinase inhibitors on ATPase activities. *Chemico-Biological Interactions*, **1993**, 86, 17-27	5	14
105	Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption. *BMC Musculoskeletal Disorders*, **2010**, 11, 250	2.8	13
104	Studies of the melatonin binding site location onto quinone reductase 2 by directed mutagenesis. *Archives of Biochemistry and Biophysics*, **2008**, 477, 12-9	4.1	13
103	Endothelin-1 inhibits TNF alpha-induced iNOS expression in 3T3-F442A adipocytes. *British Journal of Pharmacology*, **2003**, 139, 935-44	8.6	13
102	Synthesis of a small library of phenylalkylamide derivatives as melatoninergic ligands for human mt1 and MT2 receptors. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 163-71	3.4	13
101	Drug-induced hydrogen peroxide production in isolated rat hepatocytes. *Toxicology*, **1989**, 54, 129-37	4.4	13
100	The five dimensions of receptor pharmacology exemplified by melatonin receptors: An opinion. *Pharmacology Research and Perspectives*, **2020**, 8, e00556	3.1	13
99	New MT□Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	12
98	Effect of oxime ether incorporation in acyl indole derivatives on PPAR subtype selectivity. *ChemMedChem*, **2012**, 7, 2179-93	3.7	12

97	S32212, a novel serotonin type 2C receptor inverse agonist/β2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 340, 750-64	4.7	12
96	Molecular Pharmacology of NRH:Quinone Oxidoreductase 2: A Detoxifying Enzyme Acting as an Undercover Toxifying Enzyme. *Molecular Pharmacology*, **2020**, 98, 620-633	4.3	12
95	Characterization of cofactors, substrates and inhibitor binding to flavoenzyme quinone reductase 2 by automated supramolecular nano-electrospray ionization mass spectrometry. *International Journal of Mass Spectrometry*, **2012**, 312, 87-96	1.9	11
94	Crystallization via tubing microfluidics permits both in situ and ex situ X-ray diffraction. *Acta Crystallographica Section F, Structural Biology Communications*, **2017**, 73, 574-578	1.1	11
93	High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice. *PLoS ONE*, **2013**, 8, e63861	3.7	11
92	Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3. *European Journal of Medicinal Chemistry*, **2011**, 46, 1622-9	6.8	11
91	High-throughput screening assay for new ligands at human melatonin receptors. *Acta Pharmacologica Sinica*, **2008**, 29, 1515-21	8	11
90	The use of IRES-based bicistronic vectors allows the stable expression of recombinant G-protein coupled receptors such as NPY5 and histamine 4. *Biochimie*, **2006**, 88, 737-46	4.6	11
89	Design, synthesis and in vitro evaluation of novel derivatives as serotonin N-acetyltransferase inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2002**, 17, 409-14	5.6	11
88	SVK14 cells express an MCH binding site different from the MCH1 or MCH2 receptor. *Biochemical and Biophysical Research Communications*, **2002**, 295, 841-8	3.4	11
87	Physico-chemical and biological analysis of true combinatorial libraries. *Biomedical Applications*, **1999**, 725, 17-37		11
86	Design, synthesis and in vitro evaluation of novel benzo[b]thiophene derivatives as serotonin N-acetyltransferase (AANAT) inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2003**, 18, 119-25	5.6	10
85	Chromatographic assay and peptide substrate characterization of partially purified farnesyl- and geranylgeranyltransferases from rat brain cytosol. *Archives of Biochemistry and Biophysics*, **1998**, 354, 83-94	4.1	10
84	N-myristoyl-transferase activity in cancer cells. Solubilization, specificity and enzymatic inhibition of a N-myristoyl transferase from L1210 microsomes. *FEBS Journal*, **1991**, 201, 257-63		10
83	Purification and characterization of the major tyrosine protein kinase from the human promyelocytic cell line, HL60. *FEBS Journal*, **1993**, 214, 503-14		10
82	Partial purification and characterization of a new p36/40 tyrosine protein kinase from HL-60. *Biochemical and Biophysical Research Communications*, **1989**, 160, 1203-11	3.4	10
81	Further validation of the Mulder and van Doorn kinetic procedure for the measurement of microsomal UDP-glucuronosyltransferase activities. *Biochemical Journal*, **1988**, 252, 930-1	3.8	10
80	Effect of pretreatment with hydroxylated xenobiotics on the activities of rat liver UDP-glucuronosyl-transferases. *Xenobiotica*, **1983**, 13, 755-61	2	10

79	Inhibition of microsomal NAD(P)H oxidation by Triton X-100. *Journal of Proteomics*, **1986**, 13, 171-8		10
78	UDP-glucuronosyltransferase activities in human liver microsomes and in some laboratory animal species. *Biochemical Pharmacology*, **1981**, 30, 2507-10	6	10
77	Melatonin controversies, an update. *Journal of Pineal Research*, **2021**, 70, e12702	10.4	10
76	Gene expression profiling during hibernation in the European hamster. *Scientific Reports*, **2018**, 8, 13167	4.9	10
75	Characterization of novel checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors. *Life Sciences*, **2011**, 89, 259-68	6.8	9
74	Peripheral injections of melanin-concentrating hormone receptor 1 antagonist S38151 decrease food intake and body weight in rodent obesity models. *Frontiers in Endocrinology*, **2012**, 3, 160	5.7	9
73	S38151 [p-guanidinobenzoyl-[Des-Gly(10)]-MCH(7-17)] is a potent and selective antagonist at the MCH(1) receptor and has anti-feeding properties in vivo. *Peptides*, **2009**, 30, 1997-2007	3.8	9
72	A zinc chelator inhibiting gelatinases exerts potent in vitro anti-invasive effects. *European Journal of Pharmacology*, **1998**, 351, 225-33	5.3	9
71	Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one. *European Journal of Medicinal Chemistry*, **2008**, 43, 1730-6	6.8	9
70	Synthesis of new arylalkoxy amido derivatives as melatoninergic ligands. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 789-800	3.4	9
69	Liquid chromatographic assay for the measurement of glucuronidation of arylcarboxylic acids using uridine diphospho-[U-14C] glucuronic acid. *Biomedical Applications*, **1986**, 383, 51-60		9
68	S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization. *Molecular Pharmacology*, **2019**, 95, 269-285	4.3	9
67	□□F nuclear magnetic resonance screening of glucokinase activators. *Analytical Biochemistry*, **2015**, 477, 62-8	3.1	8
66	Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II). *European Journal of Medicinal Chemistry*, **2015**, 90, 822-33	6.8	8
65	Molecular basis of agonist docking in a human GPR103 homology model by site-directed mutagenesis and structure-activity relationship studies. *British Journal of Pharmacology*, **2014**, 171, 4425-39	8.6	8
64	Substrate phosphorylation capacities of the major tyrosine protein kinase from the human promyelocytic cell line, HL-60. *International Journal of Peptide and Protein Research*, **1994**, 43, 496-504		8
63	Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries. *Canadian Journal of Physiology and Pharmacology*, **1997**, 75, 683-689	2.4	8
62	Assessment of a high-throughput screening methodology for the measurement of purified UCP1 uncoupling activity. *Analytical Biochemistry*, **2006**, 351, 201-6	3.1	8

61	Synthesis of 5-substituted-2,3-dihydro-1,4-benzoxathiins: biological evaluation as melatonin receptors ligands. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2003**, 18, 187-93	5.6	8
60	Design and synthesis of indole and tetrahydroisoquinoline hydantoin derivatives as human chymase inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2004**, 19, 137-43	5.6	8
59	In vivo characterisation of the human UCP3 gene minimal promoter in mice tibialis anterior muscles. *Biochemical and Biophysical Research Communications*, **2003**, 311, 583-91	3.4	8
58	High-capacity screening of arylalkylamine N-acetyltransferase inhibitors using a high-performance liquid chromatography system. *Journal of Biomolecular Screening*, **2000**, 5, 361-8		8
57	Rat liver microsomal 3 alpha-hydroxysteroid dehydrogenase and dihydrodiol dehydrogenase: solubilization, separation and partial purification. *Biochemical and Biophysical Research Communications*, **1986**, 135, 795-801	3.4	8
56	Use of the main tyrosine protein kinase activity purified from HL-60 in the search for a new class of anticancer compounds. *Anticancer Research*, **1990**, 10, 197-201	2.3	8
55	W2476 ameliorates β-cell dysfunction and exerts therapeutic effects in mouse models of diabetes via modulation of the thioredoxin-interacting protein signaling pathway. *Acta Pharmacologica Sinica*, **2017**, 38, 1024-1037	8	7
54	VHH characterization. Comparison of recombinant with chemically synthesized anti-HER2 VHH. *Protein Science*, **2019**, 28, 1865-1879	6.3	7
53	Role of Quinone Reductase 2 in the Antimalarial Properties of Indolone-Type Derivatives. *Molecules* , **2017**, 22,	4.8	7
52	Molecular mechanisms of transcriptional control by Rev-erbβ: An energetic foundation for reconciling structure and binding with biological function. *Protein Science*, **2015**, 24, 1129-46	6.3	7
51	Tyrosine protein kinase assays. *Biomedical Applications*, **1996**, 684, 179-99		7
50	Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative. *Cancer Chemotherapy and Pharmacology*, **1992**, 29, 367-74	3.5	7
49	Approaches to some biochemical mechanisms of action of tuftsin and analogues. *Biochemical Pharmacology*, **1991**, 41, 1411-8	6	7
48	Hamster Melatonin Receptors: Cloning and Binding Characterization of MT2 and Attempt to Clone MT3. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	7
47	New quinolinic derivatives as melatonergic ligands: Synthesis and pharmacological evaluation. *European Journal of Medicinal Chemistry*, **2017**, 127, 621-631	6.8	6
46	Importance of the Choice of a Recombinant System to Produce Large Amounts of Functional Membrane Protein hERG. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	6
45	A microplate assay for the screening of ADAMTS-4 inhibitors. *Matrix Biology*, **2006**, 25, 261-7	11.4	6
44	In vitro evaluation of glucuronidation of monohydroxylated aglycones related to quantum chemically-calculated parameters. *European Journal of Medicinal Chemistry*, **1987**, 22, 393-402	6.8	6

43	Total chemical synthesis, refolding, and crystallographic structure of fully active immunophilin calstabin 2 (FKBP12.6). *Protein Science*, **2016**, 25, 2225-2242	6.3	6
42	Journal of pineal research guideline for authors: Defining and characterizing melatonin targets. *Journal of Pineal Research*, **2021**, 70, e12712	10.4	6
41	General lack of structural characterization of chemically synthesized long peptides. *Protein Science*, **2019**, 28, 857-867	6.3	5
40	Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives. *European Journal of Medicinal Chemistry*, **2016**, 109, 360-70	6.8	5
39	Functional characterization of human neuropeptide Y receptor subtype five specific antagonists using a luciferase reporter gene assay. *Cellular Signalling*, **2005**, 17, 489-96	4.9	5
38	Development of new assays and improved procedures for the purification of recombinant human chymase. *FEBS Journal*, **2001**, 268, 5885-93		5
37	Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2000**, 361, 549-54	3.4	5
36	Screening of ligand binding on melatonin receptor using non-peptide combinatorial libraries. *Journal of Receptor and Signal Transduction Research*, **2000**, 20, 105-18	2.6	5
35	Heterogeneity of hepatic UDP-glucuronosyltransferase activities: investigations of isoenzymes involved in p-nitrophenol glucuronidation. *Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology*, **1993**, 106, 241-8		5
34	How Can Molecular Pharmacology Help Understand the Multiple Actions of Melatonin: 20 Years of Research and Trends **2018**,		5
33	Natural Inhibitors of the RhoA-p115 Complex from the Bark of Meiogyne baillonii. *Journal of Natural Products*, **2018**, 81, 1610-1618	4.9	5
32	Screening ubiquitin specific protease activities using chemically synthesized ubiquitin and ubiquitinated peptides. *Analytical Biochemistry*, **2017**, 519, 57-70	3.1	4
31	A structural study of the complex between neuroepithelial cell transforming gene 1 (Net1) and RhoA reveals a potential anticancer drug hot spot. *Journal of Biological Chemistry*, **2018**, 293, 9064-9077	5.4	4
30	Antimalarial Properties of Dunnione Derivatives as NQO2 Substrates. *Molecules*, **2019**, 24,	4.8	4
29	VHH characterization.Recombinant VHHs: Production, characterization and affinity. *Analytical Biochemistry*, **2020**, 589, 113491	3.1	4
28	Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns. *Chemical Biology and Drug Design*, **2020**, 96, 1024-1051	2.9	3
27	Synthesis, chiral resolution, absolute configuration assignment and pharmacological evaluation of a series of melatoninergic ligands. *MedChemComm*, **2014**, 5, 1303-1308	5	3
26	Mutagenic analysis in a pure molecular system shows that thioredoxin-interacting protein residue Cys247 is necessary and sufficient for a mixed disulfide formation with thioredoxin. *Protein Science*, **2012**, 21, 1323-33	6.3	3

25	Image-free assessment of protein translocation in live cells. *Current Opinion in Pharmacology*, **2009**, 9, 650-6	5.1	3
24	A quantitative assay for lysosomal acidification rates in human osteoclasts. *Assay and Drug Development Technologies*, **2011**, 9, 157-64	2.1	3
23	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase(s) activities: a new kinetic approach for the study of induction and specificity. *Journal of Pharmaceutical Sciences*, **1994**, 83, 591-6	3.9	3
22	UDP-glucuronosyltransferase(s) activities towards natural substrates in rat liver microsomes. Kinetic properties and influence of triton X-100 activation. *Pharmacological Research Communications*, **1985**, 17, 1005-15		3
21	Synthesis of a Novel Series of 8-HETE Analogs and their Biological Evaluation Towards the PPAR Nuclear Receptors. *Letters in Drug Design and Discovery*, **2008**, 5, 503-511	0.8	3
20	Chemical composition and antibacterial action of Stryphnodendron pulcherrimum bark extract, Barbatimão species: Evaluation of its use as a topical agent. *Arabian Journal of Chemistry*, **2021**, 14, 103183	5.9	3
19	Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries. *Canadian Journal of Physiology and Pharmacology*, **1997**, 75, 683-9	2.4	3
18	Fluorescent analogues of BeKm-1 with high and specific activity against the hERG channel. *Toxicon: X*, **2019**, 2, 100010	2.6	2
17	Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2010**, 25, 653-72	5.6	2
16	Receptor- and ligand-based study on novel 2,2'-bithienyl derivatives as non-peptidic AANAT inhibitors. *Journal of Chemical Information and Modeling*, **2010**, 50, 446-60	6.1	2
15	Parallel synthesis and pharmacological screening of nonpeptide ligands of the neuropeptide Y receptor subtype Y5. *Chemical Biology and Drug Design*, **2001**, 57, 419-27		2
14	Secure and Sustainable Sourcing of Plant Tissues for the Exhaustive Exploration of Their Chemodiversity. *Molecules*, **2020**, 25,	4.8	2
13	Feature-Based Molecular Network-Guided Dereplication of Natural Bioactive Products from Leaves of (Willd.) Hochr. *Metabolites*, **2021**, 11,	5.6	2
12	Apigenin and Luteolin Regulate Autophagy by Targeting NRH-Quinone Oxidoreductase 2 in Liver Cells. *Antioxidants*, **2021**, 10,	7.1	2
11	Design, Synthesis, Molecular Dynamics Simulation, and Functional Evaluation of a Novel Series of 26RFa Peptide Analogues Containing a Mono- or Polyalkyl Guanidino Arginine Derivative. *Journal of Medicinal Chemistry*, **2018**, 61, 10185-10197	8.3	2
10	From peptide libraries to optimized nonpeptide ligands in the search for S-farnesyltransferase inhibitors. *Chemical Biology and Drug Design*, **2001**, 57, 85-96		1
9	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferases activities: use and comparison of differential inductions in some mammalian species. *Comparative Biochemistry and Physiology Part B: Comparative Biochemistry*, **1987**, 87, 513-22		1
8	A putative new melatonin binding site in sheep brain, MTx: preliminary observations and characteristics. *Journal of Pharmacology and Experimental Therapeutics*, **2021**,	4.7	1

7	Biochemistry, structure, and cellular internalization of a four nanobody-bearing Fc dimer. *Protein Science*, **2021**, 30, 1946-1957	6.3	1
6	MCH-R1 Antagonist GPS18169, a Pseudopeptide, Is a Peripheral Anti-Obesity Agent in Mice. *Molecules*, **2021**, 26,	4.8	1
5	On the Organization of a Drug Discovery Platform **2018**,		1
4	Association of NQO2 With UDP-Glucuronosyltransferases Reduces Menadione Toxicity in Neuroblastoma Cells. *Frontiers in Pharmacology*, **2021**, 12, 660641	5.6	0
3	Caloxin-derived peptides for the inhibition of plasma membrane calcium ATPases. *Peptides*, **2022**, 154, 170813	3.8	0
2	Jean - Luc Fauchere (1941–2003). *Chemical Biology and Drug Design*, **2003**, 62, 185-185		
1	Further assessments of ligase LplA-mediated modifications of proteins in vitro and in cellulo. *Molecular Biology Reports*, **2021**, 1	2.8	